



APPENDIX 4D

1. Name of Entity **CardieX Limited**
ACN 113 252 234

Half year ended 31 December 2018
Reporting period 1 July 2018 to 31 December 2018
Previous period 1 July 2017 to 31 December 2017

2. Results for announcement to the market

| | 31 December 2018 \$ | 31 December 2017 \$ | % Change Up (Down) |
|---|---------------------------|---------------------------|-----------------------|
| 2.1 Revenues from continuing operations | 2,007,925 | 1,964,342 | 2.22% |
| 2.2 Loss from continuing operations after tax attributable to members | (1,365,391) | (1,081,420) | 26% |
| 2.3 Net loss attributable to members | (1,410,144) | (982,428) | 44% |
| 2.4 Proposed dividends | Nil | Nil | - |
| 2.5 Record date for dividend entitlement | N/A | N/A | - |
| 2.6 Revenues for the period increased on a year on year basis. Whilst the loss for the period has increased by \$283,971 as compared to the previous period, this has come after rationalisations to the prior year cost base, which have repositioned the operations of the Company. | | | |

These rationalisations have allowed the Company to focus on further business development and investment opportunities during the current period.

The increase in net loss is largely attributable to expenditure in relation to expansion and diversification into these new projects and product development initiatives as reported to the market.

| | 31 December 2018 Cents | 30 June 2018 Cents | % Change Up (Down) |
|--|------------------------------|--------------------------|-----------------------|
| 3. Net tangible asset per security | 0.97 cents | 0.87 cents | 12% |
| 4. There were no controlled entities gained or lost during the period. | | | |
| 5. There were no payments of dividends during the reporting period. | | | |
| 6. There is no dividend reinvestment plan in operation. | | | |

7. There are no associates or joint venture entities.
8. The Company is not a foreign entity.
9. The accounts are not subject to any audit dispute or qualification.

The Company's half year report follows.

Yours sincerely,



Jarrod White
Chief Financial Officer
28 February 2019

For further information, please contact:

Jarrod White
Chief Financial Officer

jwhite@cardiex.com

Investor Relations
Peter Taylor
+61 412 036 231

peter@nwrcommunications.com.au

About Cardiex

Cardiex Limited is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. Cardiex also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating Cardiex technology. In November 2018 Cardiex entered into an agreement with telehealth services provider, inHealth Medical Services, Inc, allowing Cardiex to acquire up to 50.5% of inHealth by way of a convertible note.